ArticleGenes and immunity2022

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients.

Stefaan W Van Gool et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.